FDA Priority-Setting Includes Fewer Meetings With NDA Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director Jenkins tells DIA that agency is making “strategic decisions” about how many sponsor meetings it can schedule.
You may also be interested in...
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.
FDA Puts “Safety First” For Post-Market Issues
Agency’s two-pronged approach to drug safety includes bolstering internal processes and equipping physicians with better tools for safe prescribing habits.